Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 
• By Eliza Slawther
The EMA is set to discuss matters relating to the re-examination of three products at its latest meeting (Shutterstock)

More from EU CHMP

More from Rare Diseases